David D. Chang, M.D., Ph.D. 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-09 5:49 pm Purchase | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 11,043,100 5.000% | 138,097 (+1.27%) | Filing |
| 2025-02-13 4:29 pm Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 10,905,003 5.100% | 940,656 (+9.44%) | Filing |
| 2024-02-14 4:32 pm Purchase | 2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 9,964,347 5.800% | 1,536,715 (+18.23%) | Filing |
| 2023-02-13 4:33 pm Purchase | 2022-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | David D. Chang, M.D., Ph.D. | 8,427,632 5.700% | 8,427,632 (New Position) | Filing |